Skip to content
glp1.howSign in

Using GLP-1s

GLP-1 super-responders (and non-responders): why weight loss varies so much

On the same drug at the same dose, one person loses 25% of their body weight and another loses almost nothing. In the tirzepatide trials, half or more of people on the higher doses lost 20% or more, but a large real-world analysis found only about 1 in 8 lost more than 15% in a year, while nearly half lost under 5%. What predicts a strong response (early weight change, drug choice, sex, diabetes, biology), why real-world results trail the trials, and what to do if you're not responding.

By the glp1.how editorial teamReviewed 5 min read

Evidence-backed

Give the same GLP-1 to a room of people and the results scatter widely. In the tirzepatide trial SURMOUNT-1, half or more of people on the two higher doses lost at least 20% of their body weight. Real life looks different. A large analysis of more than 135,000 patients found only about 1 in 8 lost more than 15% in a year, while nearly half lost less than 5%. The two ends have names, super-responders and non-responders, and researchers have learned a fair amount about what separates them.

What "super-responder" means

There's no official medical definition. Researchers usually draw the lines by how much total body weight someone loses over about a year: super-responders lose more than roughly 15–20%, non-responders lose less than 5%, and most people land in between.

How common each group is depends on whether you look at a trial or at everyday care. In a real-world analysis of 135,349 GLP-1 users, 12.5% were super-responders (>15% loss), 35.2% moderate responders (5–15%), 46.8% minimal responders (<5%), and a small group regained (Venkatakrishnan et al., Biology Methods and Protocols, 2026, DOI (external link)). Trials look much better. In SURMOUNT-1, 50% and 57% of people on tirzepatide 10 mg and 15 mg lost 20% or more over 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022, DOI (external link)), and in STEP 1, half of people on semaglutide 2.4 mg lost 15% or more at 68 weeks (Wilding et al., New England Journal of Medicine, 2021, DOI (external link)).

The real-world study can't tell us why the gap exists. It didn't track dose, titration or whether people took their medication as prescribed, and it left out people who stopped treatment. Other real-world research has found that adherence is lower in everyday use than in trials and that many people stop within the first year, which probably explains part of the difference (Thomsen et al., Diabetes, Obesity & Metabolism, 2025, DOI (external link)).

What predicts a strong response

Several factors shift the odds. None of them guarantees an outcome.

  • A fast early response. Some people say "food noise" and cravings go quiet within days of the first dose. That's anecdotal, but early weight change is a measurable signal, covered in the next section.
  • Which drug. Tirzepatide (Mounjaro, Zepbound), which acts on two hormone receptors, produced super-response more often than semaglutide (Ozempic, Wegovy). In the real-world analysis the super-responder rate was highest for Zepbound (34%) and lowest for Ozempic (10%). Comparing users of each drug in that observational data, the odds of super-response favored tirzepatide: Mounjaro versus Ozempic at an odds ratio of 2.84, and Zepbound versus Wegovy at 1.47 (Venkatakrishnan et al., Biology Methods and Protocols, 2026, DOI (external link)). That isn't a randomized head-to-head trial, so differences between the people prescribed each drug may play a part.
  • Sex. Women lose more on average and are over-represented among super-responders: about 80% of super-responders were women, versus 58–65% of the other groups. Animal studies suggest estrogen may amplify GLP-1's effect on appetite, but human evidence is still limited (Börchers & Skibicka, Endocrinology, 2024, DOI (external link)). More on this in how GLP-1s affect men vs. women.
  • Younger age. Super-responders skewed younger (mean around 51 vs 55 years).
  • Diabetes status. People with type 2 diabetes tend to lose less than people without it, roughly 9–10% versus about 15% on average in the semaglutide trials. It's one of the more consistent predictors of a smaller response. In STEP 2, adults with type 2 diabetes on semaglutide 2.4 mg lost a mean 9.6% at 68 weeks (Davies et al., Lancet, 2021, DOI (external link)).
  • Biology and the "hungry gut." Some variation is genetic. People whose obesity is driven by a strong hunger and satiety signal (the "hungry gut" pattern among the four obesity phenotypes) tend to respond especially well to these appetite-targeting drugs.
  • Dose and adherence. Reaching an effective maintenance dose and taking it consistently matters. A dose that was never raised, or doses often missed, can look like a poor response when the real problem is under-treatment.

Early response is the best predictor you have

The most useful signal is how you're doing in the first three to four months at an adequate dose. Early weight change predicts the eventual result reasonably well. In pooled liraglutide 3.0 mg trials, losing at least 4% by week 16 was the best early predictor of reaching 5% or more at one year (Fujioka et al., Obesity, 2016, DOI (external link)). That's why prescribers often use an early checkpoint to decide whether to continue, raise the dose, or change course. If you've barely moved after a few months at a proper dose, treat that as information about the drug, not a judgment of your willpower. Our guide on what to realistically expect on a GLP-1 lays out the normal arc.

Being a super-responder has trade-offs

  • More side effects. The strong drug effect behind big weight loss also tends to bring more nausea and GI symptoms. Response and side-effect burden often travel together.
  • Muscle loss. Fast, large weight loss takes more lean mass with it, so strength training and protein matter more.
  • Gallstones. Rapid weight loss raises the risk of gallbladder problems. See gallbladder disease on a GLP-1.

None of this is a reason to want a weaker response. It's a reason to manage a strong one on purpose instead of treating fast loss as free.

If you're a non-responder

Losing little is far more common than the trial headlines suggest. In real-world data nearly half of people lose under 5% in the first year. Sometimes the cause is fixable, such as missed doses or never reaching an effective dose, and it isn't a personal failing. Have a structured conversation with your prescriber instead of quietly giving up. Common next steps: confirm you've reached and stayed on an effective dose, look for things blunting the response, consider a different agent (for example, moving from semaglutide to tirzepatide helps some people who stalled), and make sure protein, activity and sleep are in place. If you responded well at first and then stalled, that's a plateau, not non-response. See does increasing your dose always mean more weight loss?

This article is general education, not medical advice. Response figures are group averages and don't predict any individual's result; decisions about continuing, switching, or dosing belong with your prescriber. Research findings above are attributed to PubMed-indexed articles with DOI links.

super-respondernon-responderresponsevariabilityweight-losspredictorstreatment

Common questions

Questions people often ask about this topic.

  • What is a GLP-1 super-responder?

    There's no official medical definition, but researchers generally call someone a super-responder if they lose more than about 15–20% of their body weight over a year, and a non-responder if they lose less than 5%. How common each is depends on the setting. In SURMOUNT-1, half or more of people on the higher tirzepatide doses lost 20% or more, but a large real-world analysis of over 135,000 users found only about 12.5% lost more than 15%, while nearly half lost under 5%. In everyday care, a weak response is more common than a dramatic one.

  • What makes someone respond so strongly to a GLP-1?

    Several things shift the odds: a fast early drop in weight, which drug you're on (tirzepatide produced super-response more often than semaglutide in real-world data), being female, younger age, not having type 2 diabetes, and biology such as a strong hunger-signal or "hungry gut" phenotype. Reaching an effective dose and taking it consistently matters too. The large real-world study didn't measure dosing or adherence, so it can't say how much of the gap with trials they explain, but other research shows adherence is lower outside trials. None of these factors guarantees an outcome.

  • How soon can I tell if I'll be a strong responder?

    Your first three to four months at an adequate dose are the best clue. In pooled liraglutide trials, losing at least 4% by week 16 best predicted reaching 5% or more at one year, which is why prescribers often use an early checkpoint to decide whether to continue, raise the dose, or change course. If you've barely moved after a few months at a proper dose, that's useful information about the drug, not a judgment of your willpower.

  • Is being a super-responder always a good thing?

    It has trade-offs. The strong drug effect behind big weight loss also tends to bring more nausea and GI side effects, faster loss takes more muscle with it, and rapid weight loss raises the risk of gallstones. That's no reason to want a weaker response. It's a reason to manage a strong one on purpose, with strength training, protein, and attention to side effects.

  • What should I do if the medication isn't working for me?

    Losing little is more common than the trial headlines suggest: in real-world data nearly half of people lose under 5% in the first year. Sometimes the cause is fixable, such as missed doses or never reaching an effective dose, and it isn't a personal failing. Have a structured conversation with your prescriber: confirm you've reached and stayed on an effective dose, look for things blunting the response, and consider switching agents (for example semaglutide to tirzepatide, which helps some people who stalled) while keeping protein, activity, and sleep in place.

Evidence

The sources behind this article, labeled by type and strength.

Supporting7

Mixed findings1

Revision history

Updated 3 times since Sep 2, 2026 · show changes
  1. v4

    Evidence sources 4 → 8

  2. v3

    Common questions revised

  3. v2

    Summary rewritten; Body revised

  4. v1

    Change tracking began

Related guides

  • Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results · Researchers now describe four "phenotypes" of obesity (hungry brain, hungry gut, emotional hunger, and slow burn), and early evidence suggests they help explain why the same GLP-1 produces very different results in different people. One newly described "hungry gut" subtype lost nearly twice as much weight on tirzepatide. What the phenotypes are, what the studies show, and what to know before paying for a phenotype test.
  • Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo · There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.
  • What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026 · The American Diabetes Association's Standards of Care is the reference most US clinicians follow, and it now puts GLP-1 medications at the center of treating diabetes with obesity. It names GLP-1s as the preferred obesity medication in type 2 diabetes, sets realistic weight-loss targets, and says the highest dose isn't always the goal. The headline 2026 change: for the first time, the ADA cautiously supports GLP-1 therapy for people with type 1 diabetes and obesity, with important safety guardrails.
  • Do GLP-1 receptors "burn out"? What long-term use actually does · A common worry is that GLP-1 receptors "burn out" with long-term use: that the drug stops working or permanently damages your natural system. Where the idea comes from, what two-year trial data show, which effect really does fade (the slowing of stomach emptying), why a plateau is a new equilibrium, and what happens to your own appetite when you stop.
  • Common mistakes people make on GLP-1 medications — and how to avoid them · Most GLP-1 setbacks come from a short list of avoidable mistakes: treating it as a quick fix, neglecting protein and strength training, rushing the dose, under-hydrating, putting up with side effects instead of managing them, and going it alone. This guide covers the common ones, why they matter, and where to find the fix for each.
  • What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease · The formula used to diagnose obesity was invented in the 1830s by an astronomer studying populations, not patients, and a lot of what we assume about obesity rests on tools and ideas never designed for the job. How the definition moved from moral failing to medical diagnosis, how it's diagnosed today, why major medical bodies classify it as a disease, why it's considered chronic, and where the stigma comes from.

Related terms

  • Tirzepatide · A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • Titration · The gradual, step-by-step increase of a medication dose over time, used to reduce side effects.
  • Food noise · A colloquial term for persistent, intrusive thoughts about food — commonly reported to diminish significantly on GLP-1 medications.
  • Zepbound · Eli Lilly's brand name for injectable tirzepatide, FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
  • Mounjaro · Eli Lilly's brand name for injectable tirzepatide, FDA-approved for type 2 diabetes (adults and children 10+) and for cardiovascular risk reduction in high-risk adults with type 2 diabetes.
  • Ozempic · Novo Nordisk's brand name for semaglutide for type 2 diabetes, sold as a weekly injection and, since May 2026 in the US, as daily Ozempic tablets.

Was this helpful?

100% of 1 found this helpful

Improve this page